Searched over 200M research papers
10 papers analyzed
These studies suggest that metformin can help with PCOS by improving BMI, menstruation, body weight, metabolism, ovarian dysfunction, and pregnancy rates, though its effectiveness on live birth rates and long-term safety remains unclear.
16 papers analyzed
20 papers analyzed
Polycystic ovary syndrome (PCOS) is a prevalent endocrine disorder characterized by a combination of symptoms including irregular menstrual cycles, hyperandrogenism, and insulin resistance. Metformin, a well-known insulin-sensitizing drug, has been extensively studied for its potential benefits in managing PCOS symptoms.
Several studies have demonstrated that metformin, particularly when combined with lifestyle modifications, can significantly reduce body mass index (BMI) and subcutaneous adipose tissue in women with PCOS. A systematic review and meta-analysis found that lifestyle changes combined with metformin led to a mean reduction in BMI and subcutaneous adipose tissue compared to lifestyle changes with a placebo . This combination also resulted in an increased number of menstrual cycles, indicating improved reproductive health .
Metformin has shown efficacy in improving ovulation rates and menstrual regularity in women with PCOS. Studies indicate that metformin alone or in combination with clomiphene citrate significantly enhances ovulation rates compared to placebo or clomiphene alone . This improvement in ovulation is crucial for women with PCOS who are trying to conceive.
The impact of metformin on pregnancy and live birth rates has been a subject of extensive research. A multicenter, double-blind, placebo-controlled randomized trial revealed that metformin significantly improved pregnancy rates and live birth rates in women with PCOS, particularly in obese women. However, other studies have shown mixed results, with some indicating no significant improvement in live birth rates when metformin is used alone or in combination with clomiphene .
Metformin is effective in reducing insulin resistance, a common issue in women with PCOS. It has been shown to lower fasting insulin levels and improve glucose tolerance, which are critical factors in managing the metabolic aspects of PCOS . Additionally, metformin has been associated with a reduction in hyperinsulinaemia and improvements in lipid profiles, further supporting its role in managing metabolic health in PCOS .
Metformin's role extends beyond metabolic and reproductive health; it also has immunomodulatory effects. Research has shown that metformin treatment in pregnant women with PCOS can modulate cytokine levels, potentially reducing the risk of pregnancy complications such as late miscarriage and preterm birth. This immunomodulatory effect is more pronounced in normal weight and overweight women compared to obese women.
When compared to other insulin-sensitizing agents like thiazolidinediones and inositols, metformin has shown comparable efficacy in improving endocrine and metabolic profiles in women with PCOS. However, combination therapies involving metformin and other agents like thiazolidinediones or myo-inositol have demonstrated superior outcomes in terms of menstrual frequency and insulin resistance .
Metformin plays a significant role in managing various aspects of PCOS, including weight management, reproductive health, metabolic health, and immunomodulation. While it is particularly effective when combined with lifestyle modifications, its benefits in improving ovulation, pregnancy rates, and metabolic parameters make it a valuable treatment option for women with PCOS. Future research should focus on long-term outcomes and the potential benefits of combination therapies to optimize PCOS management.
Most relevant research papers on this topic